Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Plasma Cell Dyscrasia”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00003887
What this trial is testing

Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation

Who this might be right for
Breast CancerChronic Myeloproliferative DisordersGestational Trophoblastic Tumor+9 more
Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)Ended earlyNCT00985907
What this trial is testing

Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaPatient Participation
University of California, San Francisco 13
Early research (Phase 1)UnknownNCT05005299
What this trial is testing

Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation

Who this might be right for
Leukemia, Myeloid, AcuteLeukemia, Lymphoblastic, Acute, L1Leukemia, Lymphoblastic, Acute, L2+3 more
Melbourne Health 18
Early research (Phase 1)Study completedNCT04811898
What this trial is testing

A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment

Who this might be right for
Multiple Myeloma, RefractoryHepatocarcinomaAdvanced Solid Tumor
Azienda Ospedaliera Universitaria Mater Domini, Catanzaro 17
Testing effectiveness (Phase 2)Study completedNCT00708292
What this trial is testing

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Novartis Pharmaceuticals 29
Testing effectiveness (Phase 2)Ended earlyNCT00720629
What this trial is testing

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Who this might be right for
Graft Versus Host Disease
H. Lee Moffitt Cancer Center and Research Institute 8
Not applicableStudy completedNCT02451592
What this trial is testing

Fungemia in Hematologic Malignancies

Who this might be right for
Acute LeukemiaChronic LeukemiaMultiple Myeloma+1 more
Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne 300
Testing effectiveness (Phase 2)Looking for participantsNCT05714839
What this trial is testing

Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 123
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439175
What this trial is testing

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 70
Not applicableActive Not RecruitingNCT05271630
What this trial is testing

Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant

Who this might be right for
Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute 69
Not applicableLooking for participantsNCT07782944
What this trial is testing

CD38 Targeted -PET/ CT for Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Guilin Medical University, China 100
Not applicableStudy completedNCT02452099
What this trial is testing

Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation.

Who this might be right for
Multiple MyelomaLymphomasLeukemias
Maria Sklodowska-Curie National Research Institute of Oncology 150
Large-scale testing (Phase 3)Study completedNCT02288741
What this trial is testing

Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy

Who this might be right for
Multiple Myeloma
WiSP Wissenschaftlicher Service Pharma GmbH 549
Post-approval studies (Phase 4)Study completedNCT00622505
What this trial is testing

Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants

Who this might be right for
Multiple Myeloma
Novartis Pharmaceuticals 121
Testing effectiveness (Phase 2)Study completedNCT00083902
What this trial is testing

Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy

Who this might be right for
Multiple Myeloma
University of Arkansas 190
Not applicableLooking for participantsNCT07305337
What this trial is testing

Randomised Controlled Trial of Artificial Intelligence-assisted Health Education

Who this might be right for
LeukaemiaMultiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), LymphomaLymphoma
Zhongnan Hospital 196
Early research (Phase 1)UnknownNCT04558853
What this trial is testing

Clinical Study of Autologous Natural Killer Cells in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Karolinska University Hospital 12
Early research (Phase 1)Looking for participantsNCT03909412
What this trial is testing

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Hackensack Meridian Health 18
Large-scale testing (Phase 3)Study completedNCT00551928
What this trial is testing

Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients

Who this might be right for
Multiple MyelomaNewly Diagnosed Patients
Fondazione EMN Italy Onlus 402
Testing effectiveness (Phase 2)WithdrawnNCT03168100
What this trial is testing

2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of Arkansas
Next Page